BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24292601)

  • 1. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
    Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
    Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
    Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
    Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.
    Su HC; Haunschild C; Chung K; Komrokian S; Boles S; Sammel MD; DeMichele A
    Cancer; 2014 Dec; 120(23):3691-8. PubMed ID: 25081546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
    Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
    Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer.
    Anderson RA; Rosendahl M; Kelsey TW; Cameron DA
    Eur J Cancer; 2013 Nov; 49(16):3404-11. PubMed ID: 23968732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.
    Su HI; Sammel MD; Green J; Velders L; Stankiewicz C; Matro J; Freeman EW; Gracia CR; DeMichele A
    Cancer; 2010 Feb; 116(3):592-9. PubMed ID: 19918920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist--gonadotropin treatment.
    Peñarrubia J; Fábregues F; Manau D; Creus M; Casals G; Casamitjana R; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2005 Apr; 20(4):915-22. PubMed ID: 15665015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).
    La Marca A; Sighinolfi G; Radi D; Argento C; Baraldi E; Artenisio AC; Stabile G; Volpe A
    Hum Reprod Update; 2010; 16(2):113-30. PubMed ID: 19793843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of breast cancer on anti-mullerian hormone levels in young women.
    Su HI; Flatt SW; Natarajan L; DeMichele A; Steiner AZ
    Breast Cancer Res Treat; 2013 Jan; 137(2):571-7. PubMed ID: 23224236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol.
    Hazout A; Bouchard P; Seifer DB; Aussage P; Junca AM; Cohen-Bacrie P
    Fertil Steril; 2004 Nov; 82(5):1323-9. PubMed ID: 15533354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute onset of ovarian dysfunction in young females after start of cancer treatment.
    Mörse H; Elfving M; Lindgren A; Wölner-Hanssen P; Andersen CY; Øra I
    Pediatr Blood Cancer; 2013 Apr; 60(4):676-81. PubMed ID: 23015461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer.
    Anderson RA; Cameron DA
    J Clin Endocrinol Metab; 2011 May; 96(5):1336-43. PubMed ID: 21325458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment.
    Janse F; Donnez J; Anckaert E; de Jong FH; Fauser BC; Dolmans MM
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1136-44. PubMed ID: 21289248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Müllerian hormone as an ovarian reserve marker in young cancer women who undergo ovarian tissue cryopreservation.
    Fabbri R; Macciocca M; Melotti C; Pasquinelli G; Vicenti R; Bacchi Reggiani ML; Terribile D; Venturoli S
    Future Oncol; 2014 Jun; 10(8):1343-51. PubMed ID: 25052745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibin B and anti-Mullerian hormone: markers of ovarian response in IVF/ICSI patients?
    Muttukrishna S; Suharjono H; McGarrigle H; Sathanandan M
    BJOG; 2004 Nov; 111(11):1248-53. PubMed ID: 15521870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation and optimal timing of measurement for outcome prediction.
    Lee JR; Kim SH; Kim SM; Jee BC; Ku SY; Suh CS; Choi YM; Kim JG; Moon SY
    Hum Reprod; 2010 Oct; 25(10):2597-604. PubMed ID: 20729237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization.
    Nardo LG; Gelbaya TA; Wilkinson H; Roberts SA; Yates A; Pemberton P; Laing I
    Fertil Steril; 2009 Nov; 92(5):1586-93. PubMed ID: 18930213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
    Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
    Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Anti-Mullerian Hormone Levels, Antral Follicle Counts, and Mean Ovarian Volumes in Chemotherapy-Induced Amenorrhea among Breast Cancer Patients: A Prospective Clinical Study.
    Ünal Ç; Ordu Ç; Özmen T; İlgun AS; Çelebi F; Baysal B; Özkurt E; Duymaz T; Erdoğan İyigün Z; Kurt S; Öztürk MA; Pilancı KN; Alço G; Yararbaş K; Kayan Tapan T; Güven DC; Soybir G; Özmen V
    Curr Oncol; 2023 Oct; 30(10):9217-9229. PubMed ID: 37887566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.